Tomivosertib (eFT-508)

DRUG2 trials

Sponsors

Effector Therapeutics

Conditions

LymphomaSolid Tumors

Phase 1

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

TerminatedNCT02937675

Effector TherapeuticsLymphoma

Start: 2017-02-08End: 2019-04-04Updated: 2020-11-02

Phase 2

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

CompletedNCT03616834

Effector TherapeuticsSolid Tumors

Start: 2018-07-25End: 2021-06-30Updated: 2023-03-22

Related Papers

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

European Journal of Cancer2021-09-2724 citations

A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.

Journal of Clinical Oncology2020-05-2014 citations